Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2021

01-12-2021 | Migraine | Research article

A universal outcome measure for headache treatments, care-delivery systems and economic analysis

Authors: Timothy J Steiner, Mattias Linde, Petra Schnell-Inderst

Published in: The Journal of Headache and Pain | Issue 1/2021

Login to get access

Abstract

Background

The first manuscript in this series delineated a model of structured headache services, potentially cost-effective but requiring formal cost-effectiveness analysis (CEA). We envisaged a need for a new outcome measure for this purpose, applicable to all forms of treatment, care and care-delivery systems as opposed to comparisons of single-modality treatments.

Conception and delineation

A literature review confirmed the lack of any suitable established measure. We prioritised construct validity, simplicity, comprehensiveness and expression in intuitive units. We noted that pain was the key burdensome symptom of migraine and episodic tension-type headache (TTH), that pain above a certain level was disabling, that it was difficult to put economic value to pain but relatively easy to do this for time, a casualty of headache leading to lost productivity. Alleviation of pain to a non-disabling level would be expected to bring restoration of function. We therefore based the measure on time spent in the ictal state (TIS) of migraine or TTH, either as total TIS or proportion of all time. We expressed impact on health, in units of time, as TIS*DW, where DW was the disability weight for the ictal state supplied by the Global Burden of Disease (GBD) studies. If the time unit was hours, TIS*DW yielded hours lived with (or lost to) disability (HLDs), in analogy with GBD’s years lived with disability (YLDs).

Utility assessment

Acute treatments would reduce TIS by shortening attack duration, preventative treatments by reducing attack frequency; health-care systems such as structured headache services would have these effects by delivering these treatments. These benefits were all measurable as HLDs-averted. Population-level estimates would be derived by factoring in prevalence, but also taking treatment coverage and adherence into account. For health-care systems, additional gains from provider-training (promoting adherence to guidelines and, therefore, enhancing coverage) and consumer-education (improving adherence to care plans), increasing numbers within populations gaining the benefits of treatments, would be measurable by the same metric.

Conclusions

The new outcome measure expressed in intuitive units of time is applicable to treatments of all modalities and to system-level interventions for multiple headache types, with utility for CEA and for informing health policy.
Literature
1.
go back to reference Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Guðmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, Ruiz de la Torre E, Saylor D, Togha M, Yu S-Y, Zebenigus M, Zenebe Zewde Y, Zidverc-Trajković J, Tinelli M on behalf of Lifting The Burden: the Global Campaign against Headache (2021) Structured headache services as the solution to the ill-health burden of headache. 1. Rationale and description. J Headache Pain 22 (in press) Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Guðmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, Ruiz de la Torre E, Saylor D, Togha M, Yu S-Y, Zebenigus M, Zenebe Zewde Y, Zidverc-Trajković J, Tinelli M on behalf of Lifting The Burden: the Global Campaign against Headache (2021) Structured headache services as the solution to the ill-health burden of headache. 1. Rationale and description. J Headache Pain 22 (in press)
3.
go back to reference Linde M, Steiner TJ, Chisholm D (2015) Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain 16:15PubMedPubMedCentralCrossRef Linde M, Steiner TJ, Chisholm D (2015) Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain 16:15PubMedPubMedCentralCrossRef
4.
go back to reference Yu J, Goodman MJ, Oderda GM (2009) Economic evaluation of pharmacotherapy of migraine pain: A review of the literature. J Pain Palliat Care Pharmacother 23:396–408PubMedCrossRef Yu J, Goodman MJ, Oderda GM (2009) Economic evaluation of pharmacotherapy of migraine pain: A review of the literature. J Pain Palliat Care Pharmacother 23:396–408PubMedCrossRef
5.
go back to reference Biddle AK, Shih Y-CT, Kwong WJ (2000) Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 20:1356–1364PubMedCrossRef Biddle AK, Shih Y-CT, Kwong WJ (2000) Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 20:1356–1364PubMedCrossRef
6.
go back to reference Ramsberg J, Henriksson M (2007) The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia 27:54–62PubMedCrossRef Ramsberg J, Henriksson M (2007) The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia 27:54–62PubMedCrossRef
7.
go back to reference Slof J, Badia X, Magaz S, Láinez MJA, Galván J, Heras J (2005) Cost-efficacy of oral triptans in the treatment of acute migraine. J Med Econ 8:27–43CrossRef Slof J, Badia X, Magaz S, Láinez MJA, Galván J, Heras J (2005) Cost-efficacy of oral triptans in the treatment of acute migraine. J Med Econ 8:27–43CrossRef
8.
go back to reference Slof J (2012) Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the ‘Act when Mild’ study. Appl Health Econ Health Policy 10:201–215PubMedCrossRef Slof J (2012) Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the ‘Act when Mild’ study. Appl Health Econ Health Policy 10:201–215PubMedCrossRef
9.
go back to reference Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN (2008) Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia 28:334–345PubMedCrossRef Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN (2008) Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia 28:334–345PubMedCrossRef
11.
go back to reference Ruggeri M, Drago C, Rosiello F, Orlando V, Santori C (2020) Economic evaluation of treatments for migraine: an assessment of the generalizability following a systematic review. PharmacoEconomics 38:473–484PubMedCrossRef Ruggeri M, Drago C, Rosiello F, Orlando V, Santori C (2020) Economic evaluation of treatments for migraine: an assessment of the generalizability following a systematic review. PharmacoEconomics 38:473–484PubMedCrossRef
12.
go back to reference American Association for the Study of Headache, International Headache Society (1998) Consensus statement on improving migraine management. Headache 38:736CrossRef American Association for the Study of Headache, International Headache Society (1998) Consensus statement on improving migraine management. Headache 38:736CrossRef
13.
go back to reference Diener H-C, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, Heinze-Kuhn K, Jürgens T, Kropp P, Meyer B, May A, Schulte L, Solbach K, Straube A, Kamm K, Förderreuther S, Gantenbein A, Petersen J, Sandor P, Lampl C (2019) Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Translational Neurosci 3:1–40CrossRef Diener H-C, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, Heinze-Kuhn K, Jürgens T, Kropp P, Meyer B, May A, Schulte L, Solbach K, Straube A, Kamm K, Förderreuther S, Gantenbein A, Petersen J, Sandor P, Lampl C (2019) Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Translational Neurosci 3:1–40CrossRef
14.
go back to reference Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS (2009) EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 16:968–981PubMedCrossRef Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS (2009) EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 16:968–981PubMedCrossRef
15.
go back to reference Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache (2019) Aids to management of headache disorders in primary care (2nd edition). J Headache Pain 20: 57 Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache (2019) Aids to management of headache disorders in primary care (2nd edition). J Headache Pain 20: 57
18.
go back to reference World Health Organization (2019) The selection and use of essential medicines. WHO, Geneva, p 504 World Health Organization (2019) The selection and use of essential medicines. WHO, Geneva, p 504
19.
go back to reference Stewart WF, Lipton RB, Simon D, Von Korff M, Liberman J (1998) Reliability of an illness severity measure for headache in a population sample of migraine sufferers. Cephalalgia 18:44–51PubMedCrossRef Stewart WF, Lipton RB, Simon D, Von Korff M, Liberman J (1998) Reliability of an illness severity measure for headache in a population sample of migraine sufferers. Cephalalgia 18:44–51PubMedCrossRef
20.
go back to reference Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Research 12:963–974CrossRef Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Research 12:963–974CrossRef
21.
go back to reference El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F: MIGSEV Group (2003) Assessing the severity of migraine: development of the MIGSEV scale. Headache 43: 628–635PubMedCrossRef El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F: MIGSEV Group (2003) Assessing the severity of migraine: development of the MIGSEV scale. Headache 43: 628–635PubMedCrossRef
22.
go back to reference Cramer JA, Silberstein SD, Winner P (2001) Development and validation of the Headache Needs Assessment (HANA) survey. Headache 41:402–409PubMedCrossRef Cramer JA, Silberstein SD, Winner P (2001) Development and validation of the Headache Needs Assessment (HANA) survey. Headache 41:402–409PubMedCrossRef
23.
go back to reference Jacobson GP, Ramadan NM, Aggarwal SK, Newman CK (1994) The Henry Ford Hospital Disability Inventory (HDI). Neurology 44:837–842PubMedCrossRef Jacobson GP, Ramadan NM, Aggarwal SK, Newman CK (1994) The Henry Ford Hospital Disability Inventory (HDI). Neurology 44:837–842PubMedCrossRef
24.
go back to reference Jacobson GP, Ramadan NM, Norris L, Newman CW (1995) Headache disability inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache 35:534–539PubMedCrossRef Jacobson GP, Ramadan NM, Norris L, Newman CW (1995) Headache disability inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache 35:534–539PubMedCrossRef
25.
go back to reference Steiner TJ, Buse DC, Al Jumah M, Westergaard ML, Jensen RH, Reed ML, Prilipko L, Mennini FS, Láinez MJA, Ravishankar K, Sakai F, Yu S-Y, Fontebasso M, Al Khathami A, MacGregor EA, Antonaci F, Tassorelli C, Lipton RB on behalf of Lifting The Burden: The Global Campaign against Headache (2018) The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. J Headache Pain 19: 15 Steiner TJ, Buse DC, Al Jumah M, Westergaard ML, Jensen RH, Reed ML, Prilipko L, Mennini FS, Láinez MJA, Ravishankar K, Sakai F, Yu S-Y, Fontebasso M, Al Khathami A, MacGregor EA, Antonaci F, Tassorelli C, Lipton RB on behalf of Lifting The Burden: The Global Campaign against Headache (2018) The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. J Headache Pain 19: 15
26.
go back to reference Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
27.
go back to reference Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRef Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRef
29.
go back to reference Wagner TH, Patrick DL, Galer BS, Berzon RA (1996) A new instrument to assess the long term quality of life effects from migraine: Development and psychometric testing of the MSQOL. Headache 36:484–492PubMedCrossRef Wagner TH, Patrick DL, Galer BS, Berzon RA (1996) A new instrument to assess the long term quality of life effects from migraine: Development and psychometric testing of the MSQOL. Headache 36:484–492PubMedCrossRef
30.
go back to reference Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache 40:204–215PubMedCrossRef Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache 40:204–215PubMedCrossRef
31.
go back to reference Pathak DS, Chisolm DJ, Weis KA (2005) Functional Assessment in Migraine (FAIM) questionnaire: Development of an instrument based upon the WHO’s International Classification of Functioning, Disability, and Health. Value Health 8:591–600PubMedCrossRef Pathak DS, Chisolm DJ, Weis KA (2005) Functional Assessment in Migraine (FAIM) questionnaire: Development of an instrument based upon the WHO’s International Classification of Functioning, Disability, and Health. Value Health 8:591–600PubMedCrossRef
32.
go back to reference Leonardi M, Steiner TJ, Scher AI, Lipton RB (2005) The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 6:429–440PubMedPubMedCentralCrossRef Leonardi M, Steiner TJ, Scher AI, Lipton RB (2005) The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 6:429–440PubMedPubMedCentralCrossRef
33.
go back to reference Steiner TJ, Stovner LJ (2019) Headache, functional impact and environment. Ch 11. In: Steiner TJ, Stovner LJ (eds) Societal impact of headache. Burden, costs and response. Springer Nature, Cham, pp 143–156CrossRef Steiner TJ, Stovner LJ (2019) Headache, functional impact and environment. Ch 11. In: Steiner TJ, Stovner LJ (eds) Societal impact of headache. Burden, costs and response. Springer Nature, Cham, pp 143–156CrossRef
34.
go back to reference Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38: 1-211 Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38: 1-211
35.
go back to reference International Headache Society Clinical Trials Subcommittee: Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener H-C, Møller Hansen J, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T (2012) Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 32: 6–38CrossRef International Headache Society Clinical Trials Subcommittee: Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener H-C, Møller Hansen J, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T (2012) Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 32: 6–38CrossRef
36.
go back to reference Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, Mitsikostas DD, Steiner TJ, Tfelt-Hansen P, on behalf of the International Headache Society Clinical Trials Subcommittee (2010) Guidelines for controlled trials of drugs in tension-type headache: Second edition. Cephalalgia 30:1–16PubMedCrossRef Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, Mitsikostas DD, Steiner TJ, Tfelt-Hansen P, on behalf of the International Headache Society Clinical Trials Subcommittee (2010) Guidelines for controlled trials of drugs in tension-type headache: Second edition. Cephalalgia 30:1–16PubMedCrossRef
37.
go back to reference Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G (1994) Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 14:156–161PubMedCrossRef Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G (1994) Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 14:156–161PubMedCrossRef
38.
go back to reference Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M (2004) Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24:947–954PubMedCrossRef Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M (2004) Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24:947–954PubMedCrossRef
39.
go back to reference Diener HC, Eikermann A, Gessner U, Göbel H, Haag G, Lange R, May A, Müller-Schwefe G, Voelker M (2004) Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 52:50–56PubMedCrossRef Diener HC, Eikermann A, Gessner U, Göbel H, Haag G, Lange R, May A, Müller-Schwefe G, Voelker M (2004) Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 52:50–56PubMedCrossRef
40.
go back to reference Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B (2005) The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25:776–787PubMedCrossRef Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B (2005) The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25:776–787PubMedCrossRef
41.
go back to reference Lange R, Schwarz JA, Hohn M (2000) Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20:663–667PubMed Lange R, Schwarz JA, Hohn M (2000) Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20:663–667PubMed
42.
go back to reference Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN (2005) Aspirin is efficacious for the treatment of acute migraine. Headache 45:283–292PubMedCrossRef Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN (2005) Aspirin is efficacious for the treatment of acute migraine. Headache 45:283–292PubMedCrossRef
43.
go back to reference MacGregor EA, Dowson A, Davies PT (2002) Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42:249–255PubMedCrossRef MacGregor EA, Dowson A, Davies PT (2002) Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42:249–255PubMedCrossRef
44.
go back to reference Martinez-Martin P, Raffaelli E Jr, Titus F (2001) Efficacy and safety of metamizol versus acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 21:604–610PubMedCrossRef Martinez-Martin P, Raffaelli E Jr, Titus F (2001) Efficacy and safety of metamizol versus acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 21:604–610PubMedCrossRef
45.
go back to reference Nebe J, Heier M, Diener HC (1995) Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 15:531–535PubMedCrossRef Nebe J, Heier M, Diener HC (1995) Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 15:531–535PubMedCrossRef
46.
go back to reference Steiner TJ, Lange R, Voelker M (2003) Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 23:59–66PubMedCrossRef Steiner TJ, Lange R, Voelker M (2003) Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 23:59–66PubMedCrossRef
47.
go back to reference Steiner TJ (2015) What efficacy measures are clinically relevant and should be used in Cochrane reviews of acute migraine trials? An alternative viewpoint. Cephalalgia 35:460–462PubMedCrossRef Steiner TJ (2015) What efficacy measures are clinically relevant and should be used in Cochrane reviews of acute migraine trials? An alternative viewpoint. Cephalalgia 35:460–462PubMedCrossRef
48.
go back to reference Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, Ackerman IN, Adamu AA, Adetokunboh O, Afarideh M, Afshin A, Agarwal SK, Aggarwal R, Agrawal A, Agrawal S, Ahmadieh H, Ahmed MB, Aichour MTE, Aichour AN, Aichour I, Aiyar S, Akinyemi RO, Akseer N, Al Lami FH, Alahdab F, Al-Aly Z, Alam K, Alam N, Alam T et al (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259CrossRef Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, Ackerman IN, Adamu AA, Adetokunboh O, Afarideh M, Afshin A, Agarwal SK, Aggarwal R, Agrawal A, Agrawal S, Ahmadieh H, Ahmed MB, Aichour MTE, Aichour AN, Aichour I, Aiyar S, Akinyemi RO, Akseer N, Al Lami FH, Alahdab F, Al-Aly Z, Alam K, Alam N, Alam T et al (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259CrossRef
49.
go back to reference Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ, Gankpe FG, Gururaj G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI, Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang Y-H, Khubchandani J, Kim YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL, Qorbani M, Ranta A, Roba KT et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954–976CrossRef Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ, Gankpe FG, Gururaj G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI, Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang Y-H, Khubchandani J, Kim YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL, Qorbani M, Ranta A, Roba KT et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954–976CrossRef
50.
go back to reference GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858CrossRef GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858CrossRef
51.
go back to reference GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204–1222CrossRef GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204–1222CrossRef
52.
go back to reference Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210PubMedCrossRef Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210PubMedCrossRef
53.
go back to reference Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ (2014) Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 15:3PubMedPubMedCentralCrossRef Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ (2014) Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 15:3PubMedPubMedCentralCrossRef
54.
go back to reference Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Steiner TJ (2014) The methodology of population surveys of headache prevalence, burden and cost: Principles and recommendations from the Global Campaign against Headache. J Headache Pain 15:5PubMedPubMedCentralCrossRef Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Steiner TJ (2014) The methodology of population surveys of headache prevalence, burden and cost: Principles and recommendations from the Global Campaign against Headache. J Headache Pain 15:5PubMedPubMedCentralCrossRef
55.
go back to reference Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703–711 Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703–711
56.
go back to reference Kothari SF, Jensen RH, Steiner TJ (2021) The relationship between headache-attributed disability and lost productivity. 1. A review of the literature. J Headache Pain 22 (in press) Kothari SF, Jensen RH, Steiner TJ (2021) The relationship between headache-attributed disability and lost productivity. 1. A review of the literature. J Headache Pain 22 (in press)
57.
go back to reference Thomas H, Kothari SF, Husøy A, Jensen RH, Katsarava Z, Tinelli M, Steiner TJ (2021) The relationship between headache-attributed disability and lost productivity. 2. Empirical evidence from population-based studies in six disparate countries. J Headache Pain 22 (in press) Thomas H, Kothari SF, Husøy A, Jensen RH, Katsarava Z, Tinelli M, Steiner TJ (2021) The relationship between headache-attributed disability and lost productivity. 2. Empirical evidence from population-based studies in six disparate countries. J Headache Pain 22 (in press)
58.
go back to reference Edmeads J, Mackell JA (2002) The economic impact of migraine: an analysis of direct and indirect costs. Headache 42:501–509PubMedCrossRef Edmeads J, Mackell JA (2002) The economic impact of migraine: an analysis of direct and indirect costs. Headache 42:501–509PubMedCrossRef
59.
60.
go back to reference Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ, Vos T (2015) Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3:e712–e723PubMedCrossRef Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ, Vos T (2015) Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3:e712–e723PubMedCrossRef
62.
go back to reference Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658PubMedCrossRef Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658PubMedCrossRef
63.
go back to reference Tfelt-Hansen PC (2015) What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A comment. Cephalalgia 35:457–459PubMedCrossRef Tfelt-Hansen PC (2015) What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A comment. Cephalalgia 35:457–459PubMedCrossRef
64.
go back to reference Grosse SD, Lollar DJ, Campbell VA, Chamie M (2009) Disability and disability-adjusted life years: not the same. Pub Health Rep 124:197–202CrossRef Grosse SD, Lollar DJ, Campbell VA, Chamie M (2009) Disability and disability-adjusted life years: not the same. Pub Health Rep 124:197–202CrossRef
Metadata
Title
A universal outcome measure for headache treatments, care-delivery systems and economic analysis
Authors
Timothy J Steiner
Mattias Linde
Petra Schnell-Inderst
Publication date
01-12-2021
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2021
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-021-01269-9

Other articles of this Issue 1/2021

The Journal of Headache and Pain 1/2021 Go to the issue